Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,100 shares, a decline of 14.7% from the March 15th total of 9,500 shares. Based on an average daily trading volume, of 113,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.7% of the company's shares are short sold. View Acorda Therapeutics' Short Interest .

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ACOR earnings forecast .

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, beating analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics shares reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com . Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , ADMA Biologics (ADMA) , InterDigital (IDCC) , Nektar Therapeutics (NKTR) , Rigel Pharmaceuticals (RIGL) , Novan (NOVN) , SCYNEXIS (SCYX) , Acasti Pharma (ACST) and Applied Materials (AMAT) .

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)

Free ACOR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.66
▼
$16.76
52-Week Range: N/A

Volume: 416,900 shs
Average Volume: 119,299 shs
Market Capitalization: $820,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Acorda Therapeutics alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

ACOR Stock News Headlines

April 15, 2024 | businesswire.com

Acorda Therapeutics Announces Delisting from Nasdaq

April 14, 2024 | americanbankingnews.com

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 14, 2024 | wsj.com

Acorda Therapeutics Inc.

April 12, 2024 | americanbankingnews.com

Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com

April 8, 2024 | msn.com

Pearl River-based Acorda Therapeutics to close; 97 jobs impacted

April 6, 2024 | finance.yahoo.com

Riskiest Junk Bonds Shunned in Europe on Rising Risk of Default

April 3, 2024 | businesswire.com

Acorda Therapeutics Announces Nasdaq Delisting Notification

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 3, 2024 | baystreet.ca

Acorda Therapeutics Files for Chapter 11 Bankruptcy

April 2, 2024 | msn.com

Crude Oil Surges Over 1%; US Factory Orders Increase In February

April 2, 2024 | benzinga.com

Why Acorda Therapeutics Stock Is Down Nearly 90%

April 2, 2024 | investorplace.com

Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?

April 2, 2024 | morningstar.com

North American Morning Briefing: Stocks Seen Weaker as Doubts Over Fed Cuts Mount

April 2, 2024 | finanznachrichten.de

Merz Therapeutics: Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

April 1, 2024 | msn.com

Acorda retires from PNP after 3 months of extended service

April 1, 2024 | msn.com

Retired PNP chief Acorda: I did my best

April 1, 2024 | marketwatch.com

Stocks to Watch: PVH, Canoo, Acorda Therapeutics

April 1, 2024 | msn.com

Acorda Therapeutics shares sink nearly 40% after bankruptcy filing

April 1, 2024 | finance.yahoo.com

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

March 26, 2024 | finance.yahoo.com

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

March 11, 2024 | finance.yahoo.com

Klick Health Launches First AI Social Media Comment Moderator for Life Sciences Industry

February 28, 2024 | stocknews.com

3 Biotech Stocks to Watch in March for Success

February 23, 2024 | benzinga.com

Acorda Therapeutics Stock (NASDAQ:ACOR), Short Interest Report

February 22, 2024 | benzinga.com

Acorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and Dates

February 20, 2024 | msn.com

Acorda: No policy vs. TikTok use in PNP

February 6, 2024 | msn.com

Acorda: PNP can’t interfere with people’s initiative for Charter change

See More Headlines

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ACOR
CUSIP: 00484M10
CIK: 1008848
Web: www.acorda.com
Phone: (914) 347-4300
Fax: 914-347-4560
Employees: 111
Year Founded: 1995

Profitability

EPS (Most Recent Fiscal Year): ($203.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-252,850,000.00
Net Margins: -214.95%
Pretax Margin: -251.65%
Return on Equity: -2,206.93%
Return on Assets: -83.28%

Debt

Debt-to-Equity Ratio: 3.07
Current Ratio: 0.33
Quick Ratio: 0.26

Sales & Book Value

Annual Sales: $117.63 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 0.02
Book Value: ($127.17) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,240,000
Free Float: 1,210,000
Market Cap: $820,000.00
Optionable: No Data
Beta: 1.40

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Ron Cohen M.D. (Age 68)
Founder, CEO, President & Director
Comp: $984.15k
Mr. Michael A. Gesser M.B.A. (Age 61)
Chief Financial Officer
Comp: $459.15k
Mr. Kerry M. Clem (Age 54)
Chief Commercial Officer
Comp: $592.23k
Mr. Robert Morales (Age 56)
Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller
Ms. Felicia Vonella
Vice President of Investor Relations
Mr. Neil S. Belloff Esq. (Age 64)
General Counsel & Corporate Secretary
Ms. Tierney Saccavino
Executive Vice President of Corporate Communications
Ms. Denise J. Duca
Executive Vice President of Human Resources
Mr. Andrew Mayer J.D.
Senior Vice President
Sofia Ali
Senior VP of Operations & Strategic Planning

Key Competitors

View All Competitors

ACOR Stock Analysis - Frequently Asked Questions

Are investors shorting Acorda Therapeutics?: Acorda Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,100 shares, a decline of 14.7% from the March 15th total of 9,500 shares. Based on an average daily trading volume, of 113,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.7% of the company's shares are short sold.
View Acorda Therapeutics' Short Interest.
When is Acorda Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ACOR earnings forecast.
How were Acorda Therapeutics' earnings last quarter?: Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, beating analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%.
When did Acorda Therapeutics' stock split?: Acorda Therapeutics shares reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?: 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Acorda Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).
How do I buy shares of Acorda Therapeutics?: Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACOR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

About Acorda Therapeutics Stock (NASDAQ:ACOR)

ACOR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ACOR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info